Definition
The mRNA-LNP platform enables delivery of messenger RNA via lipid nanoparticles (LNPs), protecting mRNA from degradation and promoting efficient cellular uptake and protein expression.
Clinical Value
Following the success of COVID-19 mRNA vaccines, this delivery technology has demonstrated strong safety, immunogenicity, and scalability. mRNA-LNPs are now being rapidly developed for vaccines, gene therapy, protein replacement, and immuno-oncology applications.
OranssiBio Advantages
- 01
Fully integrated platform covering IVT mRNA synthesis, LNP encapsulation, purification, and sterile filling - 02
In-house design and production capabilities for sequence engineering and LNP formulation - 03
Flexible lipid component selection (e.g., ionizable lipid, PEG-lipid, helper lipids) - 04
Full suite of analytical tools to assess particle size, zeta potential, encapsulation rate, mRNA integrity, and more
Service Highlights
mRNA sequence design and IVT production (with 5’ capping, 3’ poly-A tail)
LNP formulation optimization for encapsulation efficiency and delivery performance
Aseptic formulation and fill/finish
IND-enabling documentation and preclinical study support
Animal model testing and data analysis available
Key Specifications
| Technical Specifications | Technical Parameters |
|---|---|
| Particle size | 80–120 nm |
| Encapsulation efficiency | >90% |
| Encapsulation method | Microfluidics |
| Scale | R&D through GMP (>200 doses per batch) |
| QC methods | HPLC, NTA, gel electrophoresis, integrity, pH, endotoxin, etc. |
